KRAS and neoplasm: To study oncogenic Kras signaling, we employed tumor cells from an inducible mouse model of PDAC (iKras), in which oncogenic KrasG12D expression can be controlled by the administration of Doxycycline (Dox) (Ying et al, 2012).